Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy - The NINDS suburban hospital stroke center experience

被引:77
作者
Lattimore, SU
Chalela, J
Davis, L
DeGraba, T
Ezzeddine, M
Haymore, J
Nyquist, P
Baird, AE
Hallenbeck, J
Warach, S
机构
[1] NINDS, Stroke Branch, Bethesda, MD 20892 USA
[2] Natl Naval Med Ctr, Dept Neurol, Clin Stroke Res Unit, Bethesda, MD USA
[3] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA
[4] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA
[5] Washington Adventist Hosp, Ctr Neurosci Serv, Takoma Pk, MD USA
[6] INOVA Fairfax Hosp, Stroke Program, Falls Church, VA USA
关键词
emergency medical services; hospital planning; stroke units; stroke; acute; thrombolytic therapy;
D O I
10.1161/01.STR.0000073789.12120.F3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-To increase the proportion of ischemic stroke patients treated with thrombolytic therapy, the establishment of primary stroke centers in community hospitals has been advocated. We evaluated the use of thrombolytic therapy before and after institution of a primary stroke center in a community hospital. Methods-The availability of an on-call stroke emergency response team was the only significant additional resource required for this hospital. All eligible patients were treated with intravenous tissue plasminogen activator (tPA). The number of patients with cerebrovascular disease, number and proportion of patients treated with tPA, times to treatment, and patient outcomes were recorded during the first 2 years of the stroke center. Results-During the 12 months before institution of the stroke center, 3 ischemic stroke patients (1.5%) were treated with tPA. During the 2-year period of around-the-clock coverage, 44 of 420 ischemic stroke patients (10.5%) were treated with intravenous tPA, a significant increase in tPA use (P<0.0001). Conclusions-Establishment of a primary stroke center at a community hospital resulted in a substantial increase in the proportion of patients receiving thrombolytic therapy for ischemic stroke. If this experience is generalized, the beneficial impact of primary stroke centers on stroke outcomes and costs to the healthcare system may be substantial.
引用
收藏
页码:E55 / E57
页数:3
相关论文
共 11 条
[1]   Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke - A statement for healthcare professionals from a special writing group of the stroke council, American Heart Association [J].
Adams, HP ;
Brott, TG ;
Furlan, AJ ;
Gomez, CR ;
Grotta, J ;
Helgason, CM ;
Kwiatkowski, T ;
Lyden, PD ;
Marler, JR ;
Torner, J ;
Feinberg, W ;
Mayberg, M ;
Thies, W .
CIRCULATION, 1996, 94 (05) :1167-1174
[2]   Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study [J].
Albers, GW ;
Bates, VE ;
Clark, WM ;
Bell, R ;
Verro, P ;
Hamilton, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1145-1150
[3]   Recommendations for the establishment of primary stroke centers [J].
Alberts, MJ ;
Hademenos, G ;
Latchaw, RE ;
Jagoda, A ;
Marler, JR ;
Mayberg, MR ;
Starke, RD ;
Todd, HW ;
Viste, KM ;
Girgus, M ;
Shephard, T ;
Emr, M ;
Shwayder, P ;
Walker, MD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (23) :3102-3109
[4]   TIME OF HOSPITAL PRESENTATION IN PATIENTS WITH ACUTE STROKE [J].
BARSAN, WG ;
BROTT, TG ;
BRODERICK, JP ;
HALEY, EC ;
LEVY, DE ;
MARLER, JR .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (22) :2558-2561
[5]   Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke [J].
Fagan, SC ;
Morgenstern, LB ;
Petitta, A ;
Ward, RE ;
Tilley, BC ;
Marler, JR ;
Levine, SR ;
Broderick, JP ;
Kwiatkowski, TG ;
Frankel, M ;
Brott, TG ;
Walker, MD .
NEUROLOGY, 1998, 50 (04) :883-890
[6]   Intravenous tissue-type plasminogen activator therapy for ischemic stroke - Houston experience 1996 to 2000 [J].
Grotta, JC ;
Burgin, WS ;
El-Mitwalli, A ;
Long, M ;
Campbell, M ;
Morgenstern, LB ;
Malkoff, M ;
Alexandrov, AV .
ARCHIVES OF NEUROLOGY, 2001, 58 (12) :2009-2013
[7]   Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers - The influence of ethnicity [J].
Johnston, SC ;
Fung, LH ;
Gillum, LA ;
Smith, WS ;
Brass, LM ;
Lichtman, JH ;
Brown, AN .
STROKE, 2001, 32 (05) :1061-1067
[8]   Use of tissue-type plasminogen activator for acute ischemic stroke - The Cleveland area experience [J].
Katzan, IL ;
Furlan, AJ ;
Lloyd, LE ;
Frank, JI ;
Harper, DL ;
Hinchey, JA ;
Hammel, JP ;
Qu, A ;
Sila, CA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1151-1158
[9]   TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE [J].
MARLER, JR ;
BROTT, T ;
BRODERICK, J ;
KOTHARI, R ;
ODONOGHUE, M ;
BARSAN, W ;
TOMSICK, T ;
SPILKER, J ;
MILLER, R ;
SAUERBECK, L ;
JARRELL, J ;
KELLY, J ;
PERKINS, T ;
MCDONALD, T ;
RORICK, M ;
HICKEY, C ;
ARMITAGE, J ;
PERRY, C ;
THALINGER, K ;
RHUDE, R ;
SCHILL, J ;
BECKER, PS ;
HEATH, RS ;
ADAMS, D ;
REED, R ;
KLEI, M ;
HUGHES, S ;
ANTHONY, J ;
BAUDENDISTEL, D ;
ZADICOFF, C ;
RYMER, M ;
BETTINGER, I ;
LAUBINGER, P ;
SCHMERLER, M ;
MEIROSE, G ;
LYDEN, P ;
RAPP, K ;
BABCOCK, T ;
DAUM, P ;
PERSONA, D ;
BRODY, M ;
JACKSON, C ;
LEWIS, S ;
LISS, J ;
MAHDAVI, Z ;
ROTHROCK, J ;
TOM, T ;
ZWEIFLER, R ;
DUNFORD, J ;
ZIVIN, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1581-1587
[10]   Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals [J].
Reed, SD ;
Cramer, SC ;
Blough, DK ;
Meyer, K ;
Jarvik, JG .
STROKE, 2001, 32 (08) :1832-1839